So, without knowing what the coming days to weeks
Post# of 148288
(Total Views: 642)
Posted On: 06/05/2022 6:04:21 PM
So, without knowing what the coming days to weeks shall bring, I'd would then say, that, at a minimum, CytoDyn, has reached a goal to publish this abstract on the Pooled Analysis of 3 Clinical Trials in mTNBC within the Journal of Clinical Oncology.
I believe it is noticed by new hearers. I also know the information to be old and has been known more than 8 months.
Given the relevance of the data, it was likely continued until at least 14 of the 28 were dead. How many were alive in November? More than 14, because OS was 12.5 months and it was still counting. More than likely, the 9 that were treated with 350mg were all dead even before November. That leave 19. We know that at least 14 of the 19 were alive in November.
The question becomes, at the rate they were going, how much longer would it take for 6 more to die which would leave only (19-6=) 13 living which is less than 50% of the 28, when these patients could have started dying even by June of 2021?
With the median age of 52, they were younger, but still plagued by immunosuppressive effects of chemo. However, Maximum ECOG of only 1, which means: "Symptomatic but completely ambulatory. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work)." who less than 1/2 the patient had. The rest had a ECOG of 0 & were asymptomatic. 23 had mets. Let's assume all 9 that got 350mg also had mets & died off. That leaves 14 yet with mets. With the Average PFS 6.1 months, let's assume patient's started dying relatively soon after the CTCs and CAMLs started returning, say 3-4 months later with some patients lasting longer.
Starting early from June 2021, but making the death rate linear of one every other month:
2021-2022
Jun-1, July-0, Patient dead 10. Remaining 18;
Aug-1, Sept -0, Patient dead 11, Remaining 17;
Oct-1, Nov-0, Patient dead 12, Remaining 16;
Dec-1, Jan-0, Patient dead 13, Remaining 15;
Feb-1, Mar-0, Patient dead 14, Remaining 14
Apr-1, May-0, Patient dead 15, Remaining 13 >> Overall Survivability 16.5 mos. Progression Free Survival would also have increased which would have been closer to 10-12 months if data resembled the above.
Hopefully it was continued and it even exceeds this.
I believe it is noticed by new hearers. I also know the information to be old and has been known more than 8 months.
Given the relevance of the data, it was likely continued until at least 14 of the 28 were dead. How many were alive in November? More than 14, because OS was 12.5 months and it was still counting. More than likely, the 9 that were treated with 350mg were all dead even before November. That leave 19. We know that at least 14 of the 19 were alive in November.
The question becomes, at the rate they were going, how much longer would it take for 6 more to die which would leave only (19-6=) 13 living which is less than 50% of the 28, when these patients could have started dying even by June of 2021?
With the median age of 52, they were younger, but still plagued by immunosuppressive effects of chemo. However, Maximum ECOG of only 1, which means: "Symptomatic but completely ambulatory. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work)." who less than 1/2 the patient had. The rest had a ECOG of 0 & were asymptomatic. 23 had mets. Let's assume all 9 that got 350mg also had mets & died off. That leaves 14 yet with mets. With the Average PFS 6.1 months, let's assume patient's started dying relatively soon after the CTCs and CAMLs started returning, say 3-4 months later with some patients lasting longer.
Starting early from June 2021, but making the death rate linear of one every other month:
2021-2022
Jun-1, July-0, Patient dead 10. Remaining 18;
Aug-1, Sept -0, Patient dead 11, Remaining 17;
Oct-1, Nov-0, Patient dead 12, Remaining 16;
Dec-1, Jan-0, Patient dead 13, Remaining 15;
Feb-1, Mar-0, Patient dead 14, Remaining 14
Apr-1, May-0, Patient dead 15, Remaining 13 >> Overall Survivability 16.5 mos. Progression Free Survival would also have increased which would have been closer to 10-12 months if data resembled the above.
Hopefully it was continued and it even exceeds this.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼